Search results
Showing 7981 to 7995 of 8907 results
This guideline has been updated and replaced by NICE guideline NG246.
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guidance has been updated and replaced by NICE guideline NG203.
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline has been updated and replaced by NICE guideline NG245.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)
Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.
Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.
Discontinued Reference number: GID-DT9
This advice has been updated and replaced by NICE healthtech guidance 562.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)
This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.
Mepilex Border dressings for preventing pressure ulcers (MIB124)
This advice has been updated and replaced by NICE medical technologies guidance 40.
Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)
This advice has been replaced by NICE HealthTech guidance 521.